A open-label study of entecavir for chronic hepatitis B to determine the optimum duration of administration

A open-label study of entecavir for chronic hepatitis B to determine the optimum duration of administration - GLSG,2006,CHB

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000644

Enrollment

Registered

2014-01-01

Start date

2006-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis B

Interventions

The group of Entecavir administration up to one year after the loss of serum HBV-DNA The group of Entecavir administration up to two years after the loss of serum HBV-DNA

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.The cases that are not given a nucleic acid analog for chronic hepatitis B. 2.The cases that were given lamivudine have no YMDD mutation and show the serum HBV-DNA-positive.

Exclusion criteria

Exclusion criteria: 1. During pregnancy and the possibility of pregnancy 2. Participating in the other clinical trials

Design outcomes

Primary

Measure	Time frame
The recurrence rate after completing Entecavir administration, the rate of loss of serum HBV-DNA, the rate of improvement of transaminase, the rate of HBeAg seroconversion	—

Countries

Japan

Contacts

Public ContactKen Sato

Gunma University Graduate School of Medicine Department of Medicine and Molecular Science

satoken@gunma-u.ac.jp027-220-8127

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026